Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 09-23 15:00:00

23.13

+0.00

0.00%

High23.40	Low23.01	Vol18.29M
Open23.13	D1 Closing23.13	Amplitude1.69%
Mkt Cap61.76B	Tradable Cap48.99B	Total Shares2.67B
T/O425.00M	T/O Rate0.86%	Tradable Shares2.12B
P/B1.27	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":23.13,"timestamp":1790146800000,"preClose":23.13,"halted":0,"volume":18292541,"delay":0,"changeRate":0,"floatShares":2118000000,"shares":2670000000,"eps":1.2695,"marketStatus":"Closed","change":0,"latestTime":"09-23 15:00:00","open":23.13,"high":23.4,"low":23.01,"amount":425000000,"amplitude":0.0169,"askPrice":23.14,"askSize":242,"bidPrice":23.13,"bidSize":113,"shortable":0,"etf":0,"ttmEps":1.2695,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790213400000},"marketStatusCode":5,"adr":0,"adjPreClose":23.13,"symbolType":"stock","openAndCloseTimeList":[[1790127000000,1790134200000],[1790139600000,1790146800000]],"highLimit":25.44,"lowLimit":20.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.27,"roa":"--","peRate":18.219772,"roe":"3.53%","epsLYR":1.27,"committee":-0.284832,"marketValue":61767000000,"turnoverRate":0.0086,"status":2,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":17.91,"timestamp":1790150894004,"preClose":18.09,"halted":0,"volume":2423809,"delay":0,"premium":"-33.79"},"floatMarketCap":49001000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2669358107","title":"Shanghai Fosun Unit Gets Global License for Two TCE Cancer Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2669358107","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669358107?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:17","pubTimestamp":1790158640,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   unit Shanghai Henlius Biotech  signed a collaboration and exclusive license deal with Amberstone Biosciences for two T-cell engager products, according to a Wednesday Shanghai bourse filing.Under the deal, Henlius Biotech received exclusive global rights to research, develop, manufacture and commercialize the products for all human uses based on Amberstone's T-MATE technology platform and two designated targets.Henlius Biotech will pay Amberstone up to $236.2 million in upfront, research, development and regulatory milestone payments, plus up to $652 million in sales milestones, it said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK0096","BK1191","BK0175","02696","02196","BK0183","BK0188","BK0060","BK0012","BK0187","BK4588","600196","HK0000306685.HKD","BK0028","BK4585","XBI","BK4581","HK0000165453.HKD","HK0000320264.USD","BK0239","HK0000320223.HKD","BK0196","BK1161","HK0000306701.USD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173167851","title":"Fosun Pharma Unit Secures Exclusive Global License for T-MATE™ Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1173167851","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173167851?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:56","pubTimestamp":1790153777,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SH: 600196) announced that its controlling subsidiary Henlius has entered into a Collaboration and License Agreement with Amberstone on September 23,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0060","600196","BK0183","BK1515","BK0188","BK1191","BK0196","BK0012","BK0028","02196","BK0187","BK0096","BK0175","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109124","title":"Shanghai Fosun Pharmaceutical Group Says Unit Signed Licensing Deal with Amberstone for Tce Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669109124?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:41","pubTimestamp":1790152884,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL4N45F0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0175","BK0188","BK0028","BK0060","BK0187","BK0012","BK0239","BK0183","BK0096","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157570307","title":"Fosun Pharma Spends HK$22.24 Million to Buy Back 1.3 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1157570307","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157570307?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:01","pubTimestamp":1789552883,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that on September 16, 2026, it expended HK$22,243,860 to repurchase 1.3 million shares of the company.The buyback transaction reflects the company's ongoing capital...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0196","BK1515","BK0060","BK1191","HELS","BK0012","BK1593","BK0096","BK0187","02196","600196","BK0239","BK0188","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128125870","title":"Fosun Pharma Spends HK$22.07 Million on Share Buyback on September 15","url":"https://stock-news.laohu8.com/highlight/detail?id=1128125870","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128125870?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:44","pubTimestamp":1789465484,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) made a notable market move on September 15, 2026, as the company announced the repurchase of 1.3 million of its own shares. The transaction,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0175","BK0187","BK0060","BK0183","BK1515","BK0028","BK0239","BK0012","BK0196","BK1191","BK1593","02196","600196","BK0188","HELS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104635509","title":"Fosun Pharma Spends HK$24.7 Million Buying Back 1.455 Million Shares on September 14","url":"https://stock-news.laohu8.com/highlight/detail?id=1104635509","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104635509?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:15","pubTimestamp":1789380920,"startTime":"0","endTime":"0","summary":"Fosun Pharma (HKEX: 02196) has announced that on September 14, 2026, the company repurchased 1.455 million shares at a total cost of HK$24.7051 million.The buyback reflects the company's ongoing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0175","BK1191","BK0028","BK0012","BK0183","BK1593","BK0187","02196","600196","BK0196","BK0188","BK1515","BK0060","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637538","title":"Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637538","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637538?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:43","pubTimestamp":1789361006,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's  application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.Fosun's subsidiary, Shanghai Henlius Biotech, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.K. and Canada.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","600196","BK0028","02196","BK0239","BK0187","BK1191","BK0060","BK1515","BK0175","BK0188","BK0196","BK0096","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188259168","title":"Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14","url":"https://stock-news.laohu8.com/highlight/detail?id=1188259168","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188259168?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:50","pubTimestamp":1789120228,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that the drug registration application for its self-developed denosumab biosimilar, HLX14 (recombinant anti-RANKL fully human...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IBB","LU2473716301.USD","BK0183","BK1191","BK0060","LU1992135472.HKD","BK0196","IE00B5TLWC47.USD","BK0096","BK0239","02196","BK0187","BK0012","PPH","BK0028","BK1515","600196","LU2322448791.USD","LU2272731865.HKD","LU2322448957.HKD","XPH","BK4588","BK0175","LU1992135399.USD","BK0188","LU2272731782.SGD","LU2272731600.USD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147370626","title":"Fosun Pharma Spends Approximately HK$21.86 Million on Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=1147370626","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147370626?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:38","pubTimestamp":1789119506,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced on September 11 that it repurchased 1.34 million shares for approximately HK$21.8642 million, at a price range of HK$16.14 to HK$16.5 per share.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0060","600196","BK0028","BK0012","BK0196","BK1191","BK0187","BK0239","BK0183","BK1515","02196","BK0175","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528940","title":"Shanghai Fosun Pharma Files HKEX Next-Day Return on Share Buyback at HKD 16.32 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528940","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528940?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:34","pubTimestamp":1789119298,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharma files HKEX next-day return on share buyback at HKD 16.32 eachShanghai Fosun Pharmaceutical repurchased 1,340,000 H shares on Sept. 11, 2026 for treasury.Buyback price range HKD 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDLwjm67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0175","BK0188","BK0187","BK0012","BK1230","BK0183","BK0060","BK0196","600196","00656","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108076077","title":"Fosun Pharma's New Oral Drug for Vitiligo Gets Green Light for Phase III Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1108076077","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108076077?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:21","pubTimestamp":1788956512,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. has announced that its oral candidate FXS5626 tablets (formerly project code AC-201) have received clinical trial approval from the National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","600196","BK1515","BK0196","BK0012","02196","BK0183","BK0239","BK1593","BK0188","BK0060","BK1191","BK0028","BK0187","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156059034","title":"Fosun Pharma Spends HK$2.63 Million Buying Back Shares on September 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1156059034","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156059034?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:06","pubTimestamp":1788948375,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that on September 9, 2026, the company repurchased 152,500 shares for a total consideration of HK$2.63 million.The buyback transaction was disclosed in an official...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","02196","BK1191","BK0188","600196","BK0175","BK0096","BK0012","BK0187","BK0239","BK1593","BK0060","BK0196","BK1515","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584300","title":"Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584300","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584300?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:05","pubTimestamp":1788948329,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharma files HKEX next-day return disclosing share buybackShanghai Fosun Pharmaceutical repurchased 152,500 H shares on Sept. 9 for treasury.Buyback price range HKD 17.16 to HKD 17.26; ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL8ksSbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","600196","BK1230","BK0012","BK0175","BK0196","BK0187","00656","BK0183","BK0096","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458549","title":"Sinopharm Group Stock Slips 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458549?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:32","pubTimestamp":1788942720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slid 2.1% to 15.70 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 25274.96.The stock's fall snapped a four-day winning streak.Sinopharm Group Co. Ltd. closed 30% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.2%.Trading volume totaled 5.9 million shares, compared to the 50-day average of 5.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1191","BK0028","BK4175","BK0012","BK0188","BK1515","SHTDY","BK0175","BK1593","BK0196","BK1197","BK0187","BK0096","BK0183","BK1500","LU1115378108.SGD","02196","600196","LU0640798160.USD","BK0060","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932955","title":"Shanghai Fosun Pharma - Receives Nmpa Approval for Phase Ii/Iii Clinical Trial of Fxs5626","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932955?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:44","pubTimestamp":1788860689,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0175","BK1191","BK0028","BK0012","BK0183","BK1593","BK0187","02196","600196","BK0196","BK0188","BK1515","BK0060","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665550329","title":"Fosun Pharma Industrial Wins China Approval for Fxs5626 Vitiligo Phase Ii/iii Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665550329","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665550329?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:44","pubTimestamp":1788860677,"startTime":"0","endTime":"0","summary":"Fosun Pharma Industrial wins China approval for FXS5626 vitiligo Phase II/III trialFosun Pharma Industrial won clearance in China for a Phase II/III adaptive seamless trial of FXS5626 in non-segmental","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3ClsJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0028","600196","00656","BK0183","BK0096","BK0175","BK0239","BK0060","BK0188","BK0187","BK1230","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132147233","title":"Fosun Pharma's Subsidiary Obtains Regulatory Nod for FXS5626 Tablet Trial in Vitiligo Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1132147233","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132147233?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:20","pubTimestamp":1788859248,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SH: 600196) has announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK1191","IBBQ","BK0012","BK1593","MDTX","BK0196","BK0183","BK0175","02196","BMED","PSYK","BK1515","BK0187","BK0096","IBBJ","BK0028","BK0060","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146341626","title":"Fosun Pharma Spends HK$1.18M on Share Buyback on September 7","url":"https://stock-news.laohu8.com/highlight/detail?id=1146341626","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146341626?lang=en_us&edition=fundamental","pubTime":"2026-09-07 18:02","pubTimestamp":1788775333,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (HK: 02196) has announced a share repurchase transaction executed on September 7, 2026. According to the company's official disclosure, the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK1515","BK1593","BK0060","BK0183","BK0187","BK0239","02196","BK0175","BK0028","BK1191","BK0012","BK0196","BK0188","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665900313","title":"Sinopharm Group Stock Rallies 0.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2665900313","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665900313?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:33","pubTimestamp":1788769980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. inched 0.9% higher to 15.83 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25413.12.This was the stock's third consecutive day of gains.Sinopharm Group Co. Ltd. closed 29% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 7.1%.Trading volume totaled 4.5 million shares, compared to the 50-day average of 5.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","BK0028","LU1115378108.SGD","01099","BK1500","02196","BK1191","BK0239","BK0187","BK0175","BK0096","BK0196","SHTDY","BK1593","BK0060","BK0183","BK4175","BK0012","BK0188","600196","BK1197","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665992823","title":"Fosun Pharmaceutical Extends Deadline of 81 Million Yuan Shareholder Loans to Fuyun Health; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665992823","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665992823?lang=en_us&edition=fundamental","pubTime":"2026-09-07 13:05","pubTimestamp":1788757530,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical , along with its controlling shareholder and subsidiaries, agreed to extend the shareholder loans worth 80.8 million yuan provided to Fuyun Health for another year, according to a Shanghai bourse filing over the weekend.The Chinese pharmaceutical company's Hong Kong shares jumped 7%, while Shanghai shares rose 1% during Monday's midday trade.The loans' extended maturity date will be Sept. 4, 2027, and the annual interest rate during the extension period will remain at 3.2%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0012","BK0096","BK1593","BK0188","BK1515","BK0028","BK0175","600196","BK0187","BK0060","BK0183","BK0196","BK0239","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790165828590,"stockEarnings":[{"period":"1week","weight":0.0605},{"period":"1month","weight":-0.0183},{"period":"3month","weight":0.0458},{"period":"6month","weight":-0.0696},{"period":"1year","weight":-0.2358},{"period":"ytd","weight":-0.1118}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.012},{"period":"3month","weight":-0.0386},{"period":"6month","weight":0.0162},{"period":"1year","weight":0.0323},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是注射用曲妥珠单抗（中国境内商品名：汉曲优）及曲妥珠单抗原液、汉利康（利妥昔单抗注射液）、斯鲁利单抗注射液（中国境内商品名：汉斯状）、奥康泽(奈妥匹坦帕洛诺司琼胶囊)、奕凯达（阿基仑赛注射液）、一心坦（沙库巴曲缬沙坦钠片）、汉贝泰（贝伐珠单抗注射液）、汉奈佳（马来酸奈拉替尼片）、倍稳（盐酸凯普拉生片）、珮金（拓培非格司亭注射液）、苏可欣（马来酸阿伐曲泊帕片）、汉达远（阿达木单抗注射液）、普瑞尼（普托马尼片）、达希斐（注射用A型肉毒毒素）、复可舒（抗人T细胞兔免疫球蛋白）、复迈宁（芦沃美替尼片）、欧泰乐（阿普米司特片）、地舒单抗注射液、复妥宁（枸橼酸伏维西利胶囊）、汉倍优（帕妥珠单抗注射液）、万缇乐（盐酸替那帕诺片）、旁必福（盐酸依特卡肽注射液）。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction